Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib

INTRODUCTION: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in patients with advanced non–small cell lung cancer (NSCLC). Clinical indicators of the likely survival benefit of EGFR-TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132038/
https://www.ncbi.nlm.nih.gov/pubmed/24419417
http://dx.doi.org/10.1097/JTO.0000000000000053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132038/
https://www.ncbi.nlm.nih.gov/pubmed/24419417
http://dx.doi.org/10.1097/JTO.0000000000000053

Ejemplares similares